Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AVEO Pharmaceuticals, Inc.
Seagen Inc.
Eastern Cooperative Oncology Group
Johnson & Johnson Enterprise Innovation Inc.
University of Campania Luigi Vanvitelli
Brown University
Centre Leon Berard
Azienda USL Reggio Emilia - IRCCS
Fudan University
City Clinical Oncology Hospital No 1
Sixth Affiliated Hospital, Sun Yat-sen University